SCHEMBL5947341

SCHEMBL5947341

Fc1ccc(CCNCc2cccc(OCC(F)(F)C(F)(F)F)c2)cc1C(F)(F)F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCHE P06276 7/20 0.47
▸ KDM4E B2RXH2 5/20 0.45
▸ MEN1 O00255 2/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ HTR1A P08908 1/20 0.45
▸ DRD2 P14416 1/20 0.45
▸ HTR2A P28223 1/20 0.45
▸ HTR2C P28335 1/20 0.45
▸ HTR7 P34969 1/20 0.45
▸ HTR6 P50406 1/20 0.45
▸ NOS3 P29474 1/20 0.41
▸ NOS1 P29475 1/20 0.41
▸ NOS2 P35228 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ TDP1 Q9NUW8 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ ROCK1 Q13464 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5947127 0.92 BCHE (0.50) BCHEKDM4EMEN1KMT2AHTR1A
SCHEMBL5947589 0.85 BCHE (0.47) BCHEKDM4EMEN1KMT2ANOS3
SCHEMBL5947346 0.85 KCNH2 (0.51) BCHEKDM4EMEN1KMT2ANOS3
SCHEMBL5947737 0.85 BCHE (0.47) BCHEKDM4EMEN1KMT2AHTR1A
SCHEMBL5947937 0.84 CYP1A2 (0.53) BCHEKDM4EMEN1KMT2AHTR1A
SCHEMBL5947489 0.84 KDM4E (0.62) BCHEKDM4EMEN1KMT2AHTR1A
SCHEMBL12228159 0.77 CA1 (0.57) BCHEMEN1KMT2ASMN1; SMN2
SCHEMBL5947539 0.77 BCHE (0.56) BCHEKDM4EMEN1KMT2AHTR1A
SCHEMBL12228162 0.76 BCHE (0.54) BCHEKDM4EMEN1KMT2AHTR1A
SCHEMBL5947203 0.76 KDM4E (0.66) BCHEKDM4EMEN1KMT2AHTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B BCHE 763/4885KDM4E 1970/4885MEN1 1889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback